Director Parsa Kiai filed a Form 4 with the SEC on November 6, 2026, disclosing a purchase of 661 shares of Medifast Inc. common stock on November 4, 2026, through an entity he is affiliated with.
Key Highlights
- Reporting person: Parsa Kiai, identified as a Director of Medifast Inc. (NYSE:MED)
- Transaction: Purchase (code P) of 661 shares of common stock on November 4, 2026
- Average price: $13.0255 per share, with actual prices ranging from $12.87 to $13.15
- Beneficial ownership following transaction: 21,089 shares held indirectly
- Holding entity: Shares are owned by Steamboat Capital Partners II, LP
- Ownership form: Indirect; Kiai disclaims beneficial ownership except to the extent of his pecuniary interest
Parsa Kiai's November 2026 Purchase Through Steamboat Capital Partners II
According to the filing, Parsa Kiai, a director of Medifast Inc. (NYSE:MED), reported the acquisition of 661 shares of Medifast common stock on November 4, 2026. The transaction was recorded under transaction code P, indicating an open-market purchase. The price listed is an average of $13.0255 per share, with the filing noting that actual prices paid on that date ranged from $12.87 to $13.15.
The filing discloses that the shares are owned by Steamboat Capital Partners II, LP. Steamboat Capital Partners GP, LLC serves as the general partner of that entity and is entitled to receive a performance allocation from it. Kiai is identified as the Managing Member of the general partner. The filing states that "Kiai may be deemed to have a pecuniary interest in the shares owned by II," and that "Kiai disclaims beneficial ownership of securities reported hereon except to the extent of his pecuniary interest therein." Following the reported transaction, the total amount of Medifast common stock beneficially owned indirectly by Kiai through this structure is listed as 21,089 shares.
The filing further states that the reporting person undertakes to provide, upon request to the SEC staff, the issuer, or a security holder, full information regarding the number of shares and prices at which the transaction was effected. No derivative securities transactions were reported in Table II of the form. The form was signed by Parsa Kiai and dated November 6, 2026.
What Was Disclosed
Parsa Kiai, a Medifast director, filed a Form 4 reporting an indirect purchase of 661 shares of Medifast common stock on November 4, 2026, at an average price of $13.0255, bringing indirectly held shares to 21,089.




Please wait processing your request...